XML 54 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727
Balance Sheet Components
6 Months Ended
Jun. 30, 2015
Investments Debt And Equity Securities [Abstract]  
Balance Sheet Components

4.Balance Sheet Components

Cash Equivalents and Short-term Investments

The fair values of cash equivalents and short-term investments classified as available-for-sale securities, consisted of the following (in thousands):

 

 

June 30, 2015

 

 

 

 

 

 

Gross Unrealized

 

 

 

 

 

 

Amortized

Cost

 

 

Gains

 

 

Losses

 

 

Estimated

Fair Value

 

Money market funds classified as cash equivalents

$

26,090

 

 

$

 

 

$

 

 

$

26,090

 

Corporate bonds classified as cash equivalents

 

8,045

 

 

 

 

 

 

(2

)

 

 

8,043

 

Commercial paper classified as short-term investments

 

4,394

 

 

 

 

 

 

 

 

 

4,394

 

Corporate bonds classified as short-term investments

 

216,249

 

 

 

16

 

 

 

(204

)

 

 

216,061

 

Asset backed securities classified as short-term investments

 

23,057

 

 

 

1

 

 

 

(19

)

 

 

23,039

 

U.S. Government agency securities classified as short-term

   investments

 

30,185

 

 

 

2

 

 

 

(3

)

 

 

30,184

 

Total

$

308,020

 

 

$

19

 

 

$

(228

)

 

$

307,811

 

 

 

 

December 31, 2014

 

 

 

 

 

 

Gross Unrealized

 

 

 

 

 

 

Amortized

Cost

 

 

Gains

 

 

Losses

 

 

Estimated

Fair Value

 

Money market funds classified as cash equivalents

$

8,627

 

 

$

 

 

$

 

 

$

8,627

 

Corporate bonds classified as cash equivalents

 

3,806

 

 

 

1

 

 

 

 

 

 

3,807

 

Corporate bonds classified as short-term investments

 

149,303

 

 

 

4

 

 

 

(172

)

 

 

149,135

 

Asset backed securities classified as short-term investments

 

9,546

 

 

 

 

 

 

(4

)

 

 

9,542

 

U.S. Government agency securities classified as short-term

   investments

 

4,488

 

 

 

1

 

 

 

(4

)

 

 

4,485

 

Other classified as cash equivalents

 

209

 

 

 

 

 

 

 

 

 

209

 

Total

$

175,979

 

 

$

6

 

 

$

(180

)

 

$

175,805

 

 

At June 30, 2015, the remaining contractual maturities of available-for-sale securities were less than two years. There have been no significant realized gains or losses on available-for-sale securities for the periods presented.

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

 

 

 

June 30,

 

 

December 31,

 

 

 

2015

 

 

2014

 

Research and clinical study expenses

 

$

5,714

 

 

$

2,703

 

Payroll and related expenses

 

 

4,972

 

 

 

4,205

 

Other

 

 

2,030

 

 

 

667

 

Total accrued liabilities

 

$

12,716

 

 

$

7,575